Search research articles
Contact Us
Filters
Showing results (61-70 of 116) with videos related to
Page
of 12
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
June 28, 2021
Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy
Helen Dearden, Lewis Au, Daniel Y Wang, et al.
Frontiers in Oncology
|
March 20, 2018
Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
John E Mullinax, MacLean Hall, Sangeetha Prabhakaran, et al.
Cell Reports. Medicine
|
April 16, 2025
Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific
Joseph J Sacco, Peter Kirk, Emma Leach, et al.
Cancer
|
August 18, 2016
Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies
Alain P Algazi, Katy K Tsai, Alexander N Shoushtari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 6, 2025
Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases
Sarah A Weiss, Dijana Djureinovic, Wei Wei, et al.
Ebiomedicine
|
October 10, 2019
Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma
Inna Smalley, Eunjung Kim, Jiannong Li, et al.
Pigment Cell & Melanoma Research
|
January 10, 2020
Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions
Isabella C Glitza, Keiran S M Smalley, Priscilla K Brastianos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2019
The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy
Todd C Knepper, Meagan Montesion, Jeffery S Russell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2021
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma
Daniel J Olson, Zeynep Eroglu, Bruce Brockstein, et al.
Molecular Cancer Therapeutics
|
April 24, 2024
First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0
Joseph Markowitz, Michael Shamblott, Andrew S Brohl, et al.
Page
of 12
Search research articles
Search
Showing results (61-70 of 116) with videos related to
Sort By:
Page
of 12
European Journal of Cancer (Oxford, England : 1990)
|
June 28, 2021
Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy
Helen Dearden, Lewis Au, Daniel Y Wang, et al.
Frontiers in Oncology
|
March 20, 2018
Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
John E Mullinax, MacLean Hall, Sangeetha Prabhakaran, et al.
Cell Reports. Medicine
|
April 16, 2025
Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific
Joseph J Sacco, Peter Kirk, Emma Leach, et al.
Cancer
|
August 18, 2016
Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies
Alain P Algazi, Katy K Tsai, Alexander N Shoushtari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 6, 2025
Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases
Sarah A Weiss, Dijana Djureinovic, Wei Wei, et al.
Ebiomedicine
|
October 10, 2019
Leveraging transcriptional dynamics to improve BRAF inhibitor responses in melanoma
Inna Smalley, Eunjung Kim, Jiannong Li, et al.
Pigment Cell & Melanoma Research
|
January 10, 2020
Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions
Isabella C Glitza, Keiran S M Smalley, Priscilla K Brastianos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 11, 2019
The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy
Todd C Knepper, Meagan Montesion, Jeffery S Russell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2021
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma
Daniel J Olson, Zeynep Eroglu, Bruce Brockstein, et al.
Molecular Cancer Therapeutics
|
April 24, 2024
First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0
Joseph Markowitz, Michael Shamblott, Andrew S Brohl, et al.
Page
of 12